MeiraGTx Holdings plc Liabilities, Fair Value Adjustment
MeiraGTx Holdings plc (MGTX) reported Liabilities, Fair Value Adjustment of $499.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes
us-gaap:LiabilitiesFairValueAdjustment · last filed 2025-03-13
- MeiraGTx Holdings plc liabilities, fair value adjustment for the quarter ending 2023-12-31 was $446.00K.
- MeiraGTx Holdings plc liabilities, fair value adjustment for the quarter ending 2023-09-30 was $0.00.
- MeiraGTx Holdings plc liabilities, fair value adjustment for the quarter ending 2023-06-30 was -$1.00K, a 100.40% decline year-over-year.
- MeiraGTx Holdings plc liabilities, fair value adjustment for the quarter ending 2023-03-31 was $54.00K, a 86.40% decline year-over-year.
- MeiraGTx Holdings plc liabilities, fair value adjustment for fiscal 2023 was $499.00K, a 38.23% increase from fiscal 2022.
- MeiraGTx Holdings plc liabilities, fair value adjustment for fiscal 2022 was $361.00K.
- MeiraGTx Holdings plc liabilities, fair value adjustment for fiscal 2021 was -$434.00K.
- MeiraGTx Holdings plc liabilities, fair value adjustment for fiscal 2019 was $256.00K, a 81.92% decline from fiscal 2018.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2023-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $446.00K derived: sum of 2 quarters · filed 2025-03-13 | $445.00K derived: sum of 3 quarters · filed 2025-03-13 | $499.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.00K derived: sum of 2 quarters · filed 2024-11-13 | $53.00K 10-Q · filed 2024-11-13 | -$201.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$1.00K 10-Q · filed 2024-08-12 | $53.00K 10-Q · filed 2024-08-12 | -$201.00K derived: sum of 3 quarters · filed 2024-08-12 | -$235.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $54.00K 10-Q · filed 2024-05-09 | -$200.00K derived: sum of 2 quarters · filed 2024-05-09 | -$234.00K derived: sum of 3 quarters · filed 2024-05-09 | $18.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$288.00K derived: sum of 2 quarters · filed 2024-03-15 | -$36.00K derived: sum of 3 quarters · filed 2024-03-15 | $361.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | -$34.00K 10-Q · filed 2023-11-14 | $218.00K derived: sum of 2 quarters · filed 2023-11-14 | $615.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $252.00K 10-Q · filed 2023-08-10 | $649.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $397.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$434.00K 10-K · filed 2023-03-14 | |||
| 2019-12-31 | $256.00K 10-K · filed 2020-03-11 | |||
| 2018-12-31 | $1.42M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |